AI Nose Corporation
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Ainos is transforming itself into a diversified medtech leader through three innovative business arms:
1. Pharmaceuticals – Leveraging more than 100 scientific and clinical data studies to establish the next generation of low—dose interferons solutions
1. Pharmaceuticals – Leveraging more than 100 scientific and clinical data studies to establish the next generation of low—dose interferons solutions
The content above was translated by Ai
Founded Year
2016
Unified Business No.
45050736
Status
Active
Number of Employees
0
Total Paid-in
Capital
5,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The Medical Device Division and AI Nose technology is a large step toward unlocking the final piece of medical diagnostic digitization, smell. Volatile organic compounds (VOCs) within the human body can be digitally profile and provide a future blueprint for personalized medicine. We refer to the digital ID related to VOCs as “Smell ID”. Our AI algorithms are transforming these Smell IDs into a value-added diagnostics and health acumen.
By combining leading-edge MEMS semiconductor manufacturing processes with easy-to-use, in-vitro diagnostics, point-of-care testing (IVD-POCT) devices, Ainos can quickly disseminate around the world. Within a few short years, Ainos launched AI-powered IVD-POCT devices for rapid COVID-19 detection, ventilator associated pneumonia detection, non-invasive feminine health diagnostics, and more.
By combining leading-edge MEMS semiconductor manufacturing processes with easy-to-use, in-vitro diagnostics, point-of-care testing (IVD-POCT) devices, Ainos can quickly disseminate around the world. Within a few short years, Ainos launched AI-powered IVD-POCT devices for rapid COVID-19 detection, ventilator associated pneumonia detection, non-invasive feminine health diagnostics, and more.
The content above was translated by Ai
